Cami Cowart
Family · High Springs, FLNPI 1114515723
Payments from drug & device makers
Across 98 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$482
- Novo Nordisk$404
- Pfizer$126
- GSK$81
- Astellas Pharma US Inc$75
- Boehringer Ingelheim$72
- plus $473 from 13 others
What the payments were for
- Food & beverage$1,712100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 29 | $482 |
| Novo Nordisk | 24 | $404 |
| Pfizer | 8 | $126 |
| GSK | 4 | $81 |
| Astellas Pharma US Inc | 4 | $75 |
| Boehringer Ingelheim | 3 | $72 |
| Amgen | 4 | $66 |
| Merck | 3 | $60 |
| AstraZeneca | 4 | $58 |
| AbbVie | 2 | $42 |
| Inspire Medical Systems, Inc. | 2 | $42 |
| Sanofi-aventis U.S. LLC | 2 | $40 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $36 |
| Exact Sciences | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 1 | $29 |
| Novartis | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Bayer | 1 | $14 |
How this compares
$1,712 in reported general payments places this provider in the 75th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 21 | $20,049 |
| JardianceEmpagliflozin | 14 | $12,764 |
| JanuviaSitagliptin Phosphate | 11 | $5,966 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $1,951 |
| Levothyroxine Sodium | 51 | $484 |
| Gabapentin | 23 | $377 |
| Celecoxib | 16 | $267 |
| Rosuvastatin Calcium | 25 | $254 |
| Estradiol | 17 | $253 |
| Pantoprazole Sodium | 15 | $240 |
| Potassium Chloride | 12 | $209 |
| Omeprazole | 27 | $193 |
| Atorvastatin Calcium | 38 | $178 |
| Losartan Potassium | 20 | $163 |
| Lisinopril | 18 | $137 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $404 | $20,04921 claims |
| Boehringer IngelheimJardiance | $72 | $12,76414 claims |
| MerckJanuvia | $60 | $5,96611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 14,618 family providers in Florida.
Other family in High Springs
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.